A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA045-001

To Learn More Call
(201)-510-0950